pillbase.ru

Camzyos

Active substance: mavacamten

Mavacamten

Centralised EU authorisationActive

Marketing holder: Bristol-Myers Squibb Pharma EEIG

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 4
  • CAMZYOS
    CAPSULE, GELATIN COATED · MAVACAMTEN 5 mg/1
    73625-112
    Myokardia, Inc.
  • CAMZYOS
    CAPSULE, GELATIN COATED · MAVACAMTEN 2.5 mg/1
    73625-111
    Myokardia, Inc.
  • CAMZYOS
    CAPSULE, GELATIN COATED · MAVACAMTEN 10 mg/1
    73625-113
    Myokardia, Inc.
  • CAMZYOS
    CAPSULE, GELATIN COATED · MAVACAMTEN 15 mg/1
    73625-114
    Myokardia, Inc.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-d11a-783a-9322-2faee194ca77,01a12095-1db5-7bbb-9488-cd2f40a31a8d,01a12095-1db7-73a8-aa0d-1b9b9390633b,01a12095-1db8-7a8d-b1b4-b90105f27cc1;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/005457
Registration status
Active
ATC code
C01EB
Sources
  • product · EMA · EMEA/H/C/005457 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/005457 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/005457 · Verified 2026-10-09